1. Home
  2. BY vs NVAX Comparison

BY vs NVAX Comparison

Compare BY & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BY

Byline Bancorp Inc.

HOLD

Current Price

$37.55

Market Cap

1.5B

Sector

Finance

ML Signal

HOLD

Logo Novavax Inc.

NVAX

Novavax Inc.

HOLD

Current Price

$8.88

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BY
NVAX
Founded
1914
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.5B
IPO Year
2017
1996

Fundamental Metrics

Financial Performance
Metric
BY
NVAX
Price
$37.55
$8.88
Analyst Decision
Buy
Hold
Analyst Count
2
9
Target Price
$36.00
$11.33
AVG Volume (30 Days)
271.4K
4.4M
Earning Date
04-23-2026
05-06-2026
Dividend Yield
1.48%
N/A
EPS Growth
5.09
309.76
EPS
0.83
N/A
Revenue
N/A
$1,123,479,000.00
Revenue This Year
$16.89
N/A
Revenue Next Year
$3.15
N/A
P/E Ratio
$44.33
N/A
Revenue Growth
N/A
64.69
52 Week Low
$25.38
$6.20
52 Week High
$36.90
$11.85

Technical Indicators

Market Signals
Indicator
BY
NVAX
Relative Strength Index (RSI) 76.53 46.20
Support Level $32.02 $8.89
Resistance Level N/A $9.02
Average True Range (ATR) 0.68 0.60
MACD 0.19 -0.08
Stochastic Oscillator 86.53 36.52

Price Performance

Historical Comparison
BY
NVAX

About BY Byline Bancorp Inc.

Byline Bancorp Inc is the holding company for Byline Bank, a full-service commercial bank serving small-and-medium sized businesses, financial sponsors, and consumers. The company offers a broad range of banking products and services to small and medium sized businesses, commercial real estate and online account opening to consumer and business. Also provide trust and wealth management services to its customers. In addition to traditional commercial banking business, company provide small ticket equipment leasing solutions through a wholly-owned subsidiary of Byline Bank.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

Share on Social Networks: